Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), sent a letter to President Biden outlining ways the public and private sectors can best work with global partners to ensure that patients around the world get access to COVID vaccines, therapeutics, and diagnostics. The letter, written on behalf of BIO members, highlights the importance of the COVAX and “ACT-Accelerator” initiatives to increase global vaccine access. It also makes clear industry concerns about the proposed “TRIPS waiver” in helping end this pandemic.
